sized with a propeptide domain that is cleaved at residue
tors. However, unequivocal identification of the important active site residues must await determination of the X-ray structure of BACE cocrystallized with substrate. E46 to form the mature enzyme. The sequence immediProperties of ␥-Secretase ately preceding the cleavage site is RLPR, a potential Following ␤-secretase cleavage, a second cut at the C recognition motif of proprotein convertases such as terminus of the A␤ peptide by the ␥-secretase is necesfurin, and mutation of R45 to alanine blocks propeptide sary to release A␤ from C99 (Figure 1 ). major pathogenic species because it is increased in the It remains to be determined whether processing of the various forms of familial early onset AD and is the major propeptide domain may regulate the activity of BACE. constituent of the amyloid plaques. ␥-secretase cleavRegardless, furin does not appear to be a viable AD theraages occur within the predicted transmembrane domain peutic target given its ubiquitous pattern of expression of APP, requiring ␥-secretase to either cleave within the and large number of important substrates in vivo.
lipid bilayer or change the conformation of C99 such Important questions remain concerning the design of that the cleavage sites are pulled out of the membrane BACE inhibitors for therapeutic development. Critical (for review, see Selkoe, 1999). Site-directed mutagenefor drug design will be the structural elucidation of the sis studies suggest that the enzyme has a rather broad BACE active site bound with substrate. Toward this goal, sequence specificity, quite in contrast to ␤-secretase.
Sauder et al. (2000) have modeled BACE in complex
This has led to the hypothesis that ␥-secretase may not with various APP substrates and propose that R296 and need a specific recognition sequence but may cleave several hydrophobic residues in the active site may play various type I transmembrane proteins that lack a bulky critical roles in the enzyme-substrate interaction. If the luminal or extracellular domain. ␥-secretase has not yet been purified, and much of the currently available information is derived from cell-based assays. It is unclear from these studies whether the same ␥-secretase generates both A␤40 and A␤42, or whether different enzymes are responsible for the two cleavages. Inhibitor data supporting both scenarios have been published. It appears that the majority of ␥-secretase cleavage leading to secreted A␤ takes place in late transport compartments and in the endosomal pathway. Inhibitor data suggesting that ␥-secretase may be an aspartic protease led to the mutational analysis of two tion in both 40 and 42 cleavage, and in cells from PS1/ PS2 double knockouts ␥-secretase cleavage is comconserved aspartates in transmembrane domains 6 and 7 of presenilins that were hypothesized to provide the pletely abolished (Zhang et al., 2000) .
Presenilins are not only involved in ␥-secretase cleavactive sites. When the aspartates were mutated, ␥-secretase and Notch cleavages were markedly decreased, supage: they also control the Notch signaling pathway that is important for cell fate decisions during embryogeneporting the hypothesis that PS1 and PS2 are novel aspartic proteases that cleave both APP and Notch ( Figure 3A) . However, the firm conclusion that presenilin is ␥-secretase or contains fragment pulls out soluble ␥-secretase activity (and the PS1 C-terminal fragment), indicating that PS1 expression at least the active site of a multiprotein complex with ␥-secretase activity does require the in vitro reconstituis not only required for ␥-secretase activity in intact cells, but that PS1 protein is physically associated with the tion of ␥-secretase from purified components. At this point, an alternative model in which presenilin is a critical ␥-secretase enzyme (Li et al., 2000a) . These data can be
